Legend Starts Submission for US Approval of BCMA CAR-T Therapy

Legend Bio started a rolling submission of a Biologics License Application for US approval of its BCMA CAR-T therapy. Ciltacabtagene autoleucel (cilta-cel) is indicated for adults with relapsed and/or refractory multiple myeloma. In late 2017, Legend out-licensed rights for the candidate to Janssen Pharma, a division of Johnson & Johnson, in a deal worth $350 million upfront with more than $1 billion available in milestones. The BLA filing triggered a $75 million payment to Legend. More details.... Stock Symbol: (NSDQ: LEGN) Share this with colleagues: // //